Servier, Dr. ABC , Dr. XYZ , and Medical Learning Hub, welcome you to a live CME on “Unlocking the Promise of Precision Therapy in Cholangiocarcinoma.” This session will begin with a deep dive into the current molecular diagnostic landscape of cholangiocarcinoma, led by Dr. ABC. He will shed light on practical aspects of genomic testing from tissue-based NGS and targeted assays to the expanding role of liquid biopsy while addressing challenges such as sample adequacy, test selection, and data interpretation. The session will also touch on system-level issues like variability in testing standards and access barriers, and look ahead at emerging multi-omics approaches to refine diagnosis and treatment pathways.
Following this, Dr. XYZ will present a focused clinical session on Ivosidenib as a targeted therapy for IDH1-mutated cholangiocarcinoma. Drawing from key findings from the ClarIDHy trial and real-world data, Dr. XYZ will discuss Ivosidenib’s mechanism of action, therapeutic outcomes, safety profile, and optimal use in practice.
This CME is tailored for oncologists, pathologists, and healthcare professionals involved in managing cholangiocarcinoma, offering valuable clinical insights and practical guidance to enhance precision-based care and drive better patient outcomes.
Theme topic: Unlocking the Promise of Precision Therapy in Cholangiocarcinoma | Servier
- Introduction & Welcome Note: Servier / MLH (5 Min)
- Context Setting: Moderator (10 Min)
- Session 1: Genomic Testing Lanscape for CCA – challenges and way forward (Mol Pathologist) (20 Min)
- Session 2: Personalize to maximize the benefits in CCA – Ivosidenib for IDH1 mutated patients (Mol Oncologists- a Tibsovo experience sharing) (20 Min)
- Panel Discussion + Q&A: All 3 faculty members (30 Min)
Date : 7th August 2025
- Oncologists
- Pathologists
- Microbiologists
- Consultant Physician
